| アブストラクト | PURPOSE: To investigate the real-world dose of systemic corticosteroids in the treatment of non-infectious uveitis (NIU) in Japan. STUDY DESIGN: A retrospective, observational study. METHODS: Patients newly registered at the Japan Medical Data Center health insurance claims database with a diagnosis of NIU who received systemic corticosteroids were identified, and their systemic corticosteroid dose (prednisolone equivalent) was assessed over 12 months of treatment (data extraction period: January 2008 to May 2017). RESULTS: The mean cumulative systemic corticosteroid dose in 12 months in 1641 new patients with NIU who received systemic corticosteroids was 593.7 mg. The mean systemic corticosteroid dose was highest at month 1 (10.7, 218.1, 16.7, and 23.0 mg/day in Behcet's disease [BD]-associated NIU [n = 19], Vogt-Koyanagi-Harada [VKH] disease-associated NIU [n = 49], sarcoidosis-associated NIU [n = 27], and "undifferentiated NIU" [NIU without specific primary disease information, n = 1545], respectively) and decreased over time. Systemic corticosteroids were prescribed at month 12 to 68.4%, 22.4%, 44.4%, and 5.6% of patients with BD-associated NIU, VKH disease-associated NIU, sarcoidosis-associated NIU, and undifferentiated NIU, respectively (mean dose, 6.0-14.3 mg/day). Multivariate regression analysis identified female sex, middle age (30 to < 40 years), VKH disease, and immunosuppressive agent use as background factors associated with higher systemic corticosteroid dose. CONCLUSIONS: The systemic corticosteroid dose was highest at month 1 and decreased over time in all disease categories. This database research revealed that some patients with NIU continued being prescribed systemic corticosteroids for at least 1 year. |
|---|
| ジャーナル名 | Japanese journal of ophthalmology |
|---|
| 投稿日 | 2022/6/8 |
|---|
| 投稿者 | Umazume, Akihiko; Ohguro, Nobuyuki; Okada, Annabelle A; Namba, Kenichi; Sonoda, Koh-Hei; Tsuruga, Hidekazu; Morita, Kazuo; Goto, Hiroshi |
|---|
| 組織名 | Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.;Japan Community Healthcare Organization Osaka Hospital, Osaka, Japan.;Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.;Department of Ophthalmology, Faculty of Medicine, Graduate School of Medicine,;Hokkaido University, Sapporo, Japan.;Department of Clinical Medicine, Kyushu University Faculty of Medical Sciences,;Fukuoka, Japan.;AbbVie GK, 3-1-21 Shibaura, Minato-ku, 108-0023, Tokyo, Japan.;hidekazu.tsuruga@abbvie.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35670922/ |
|---|
